LLY

Healthcare · Pharmaceuticals

1142.85

-0.61% · 2026-10-02

Avoid

Trade priority: not ranked

Data coverage: 55%

Setup: no setup · 2026-10-02

News: negative

Next catalyst: Earnings in 18 sessions

Trade plan

PRE_BREAKOUT_SWING_V1_1 · valid until close of 2026-10-05, a material event, or strategy invalidation · shared by every portfolio profile

No trade plan: the strategy has no valid setup for this symbol (trend or relative-strength condition fails (intermediate_trend, relative_strength_20)).

Your portfolio · San

profile-specific: quantity, risk budget, exposure, cash impact

Profile: Sanequity 2,000.00 USD · whole shares
Current holding: noneno open position in this profile
Recommended quantity: —no pending entry to size
Risk budget: 10.000.5% of 2,000.00
Portfolio risk: 0.00 opencap 2%
Exposure: 0 / 3 positionsHealthcare: 0 / 2 · 0.00 of 1,000.00 cap
Cash impact: 2,000.00derived from the ledger
Eligibility: AVOIDsame as the strategy view

Entry, stop, targets and R:R are strategy-owned and identical for every profile; only this portfolio's quantity, risk, exposure and cash differ. Manage profiles · record a fill

Why this action

Technical

trend or relative-strength condition fails (intermediate_trend, relative_strength_20)
RS20 vs SPY -1.0%, vs QQQ -5.9%

Options

volume 0.96× the 20D baseline (activity_accelerating) · selected contracts only, delayed

News and events

news context negative (90 canonical items in window)
earnings 2026-10-29 (18 sessions, finnhub); event risk low
fda · high · positive: Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor,
fda · high · positive: Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor
fda · high · positive: Eli Lilly Weight-Loss Drug Foundayo Meets Primary Endpoint in Phase 3 Trial
fda · high · negative: Eli Lilly Announces Detailed Results From The Phase 3 ACHIEVE-4 Trial Evaluating The Effi

Market and risk

regime RISK ON: SPY: trend UP, volatility NORMAL; QQQ: trend UP, volatility NORMAL

Chart

252 sessions · EMA20 / SMA50 / SMA150 / SMA200 default · strategy levels drawn when a plan exists

2026-10-02O 1153.82H 1164.92L 1136.66C 1142.85 -0.61%Vol 2,054,753RVOL20 0.90SMA50 1176.79SMA150 1080.72SMA200 1073.81EMA20 1162.03RSI14 43.0MACD -3.036 / -3.744 / 0.708ATR14 31.93RS20 SPY -1.0% · QQQ -5.9%

Indicator history is derived from the stored bars with the accepted M3 functions (WORKSTATION_SERIES_V1); the scanner’s persisted values remain authoritative. Reconciliation at the scan session: 8 match.

Trade priority

operational attention ranking, not a forecast

Not ranked: only valid setups and gated setups enter the trade-priority ranking.

technical readinessn/a
structure quality6/10
relative strength-0/15
participation4/10
risk rewardn/a
news context0/10
event risk5/5
urgency1/5

operational attention priority not a return forecast. Missing inputs lower coverage, never the score.

Setup evidence · PRE_BREAKOUT_V1

Setup state: NO_SETUP
Resistance: 1,185.53
Distance: 3.60%
Close: 1,142.85
SMA50: 1,176.79
SMA150 / SMA200: 1,080.72 / 1,073.81
RSI14: 43
EMA20 extension: -0.6 ATR
RS20 vs SPY: -1.0%
RS20 vs QQQ: -5.9%

Hard requirements · 4/8 passed

PASS
Confirmed resistance
resistance=1,185.5275 exists eligible=true
FAIL
Distance to resistance
distance_pct=3.5999 · resistance=1,185.5275 · close=1,142.85 inclusive_between min=0 · max=3
FAIL
Close above SMA50
close=1,142.85 · sma50=1,176.7894 > right_operand=sma50
PASS
SMA150 ≥ SMA200
sma150=1,080.722 · sma200=1,073.8146 >= right_operand=sma200
FAIL
RSI14 band
rsi14=43.0135 inclusive_between min=50 · max=70
PASS
EMA20 extension (ATR)
extension_atr=-0.6008 · close=1,142.85 · ema20=1,162.0308 · atr14=31.9264 <= max=1.5
FAIL
RS20 vs SPY or QQQ
SPY=-0.0099 · QQQ=-0.0589 OR > SPY=0 · QQQ=0
PASS
Resistance quality
distinct_touches=2 policy_and_minimum_touches min=2

Supporting evidence · 2/6 passed

PASS
ATR compression
current_atr_pct=0.0279 · median_previous_60_atr_pct=0.0321 · ratio=0.8704 < right_operand=median_previous_60_atr_pct
FAIL
Volume contraction
recent_volume=2,254,641.4087 · baseline_volume=2,345,696.0291 · ratio=0.9612 < max=0.85
FAIL
Higher lows
low_1=1,113.55 · low_2=1,113.2919 · low_3=1,134.41 low_3 > low_2 > low_1 required_pivots=3
PASS
Full MA alignment
sma50=1,176.7894 · sma150=1,080.722 · sma200=1,073.8146 sma50 > sma150 > sma200
FAIL
RS20 vs SPY positive
SPY=-0.0099 > min=0
FAIL
RS20 vs QQQ positive
QQQ=-0.0589 > min=0

PRE_BREAKOUT_V1 · scan run 414 · session 2026-10-02 · evaluated as of 2026-10-04T13:22:56.327970Z. Supporting evidence never changes the trigger; UNKNOWN is never collapsed into false.

Intelligence timeline

90 canonical of 99 items in window · duplicates collapsed

2026-10-0311:50 UTC
Eli Lilly (NYSE:LLY) Combines Strong Growth With a High-Quality Technical Setup
Eli Lilly (LLY) scores high on growth and fundamentals with a tightening chart setup, offering a defined risk line for a potential breakout.
ChartMillTier 3 · providerotherlow materialitypositivereported fact
2026-10-0219:05 UTC
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p delet
YahooTier 3 · providerfdahigh materialitypositivereported factmention in body only
2026-10-0215:41 UTC
Eli Lilly Stock Is Up 7% in 2026 as Its Obesity Pipeline Expands. Here’s Where the Stock Could Go by 2030
Key Stats for Eli Lilly StockCurrent Price: $1,149. 85Target Price (Mid): ~$2,010Street Target: ~$1,330Potential Total Return: ~75%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly (LLY:NYSE) released Phase 2b results for EloraTZP on September 30.
YahooTier 3 · providerotherlow materialitypositivecommentarymention in body only
2026-10-0215:09 UTC
Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton
BenzingaTier 3 · providerfdahigh materialitypositivereported factmention in body only
2026-10-0212:15 UTC
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
YahooTier 3 · providerotherlow materialityunknownreported fact
2026-10-0116:29 UTC
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says
Eli Lilly's (LLY) new obesity data support a broader drug portfolio beyond tirzepatide, or TZP, UBS
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-10-0116:17 UTC
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY4050784), Foghorn and Eli Lilly & Co. (NYSE:LLY) will not advance the program into clinical developmen
YahooTier 3 · providerotherlow materialitynegativereported factmention in body only
2026-10-0116:11 UTC
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Co
YahooTier 3 · providerindustrylow materialitypositivereported factmention in body only
2026-10-0115:10 UTC
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
YahooTier 3 · providerearningsmedium materialitypositivecommentary
2026-10-0113:00 UTC
Eli Lilly obesity drug data adds pressure on Novo Nordisk
Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide...
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-10-0112:48 UTC
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
YahooTier 3 · providerotherlow materialitypositivereported factmention in body only
2026-10-0111:00 UTC
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of
YahooTier 3 · providerotherlow materialityunknowncommentarymention in body only
2026-10-0108:58 UTC
Eli Lilly Weight-Loss Drug Foundayo Meets Primary Endpoint in Phase 3 Trial
Eli Lilly's (LLY) weight-loss drug, Foundayo, has met the primary endpoint in a phase 3 trial of adu
YahooTier 3 · providerfdahigh materialitypositivereported factmention in body only
2026-09-3022:00 UTC
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine i
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-09-3020:45 UTC
Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading day.
YahooTier 3 · providerotherlow materialitynegativereported fact
2026-09-3020:09 UTC
Eli Lilly (LLY) Stock Stays Undervalued As Its 437% Run Raises Stakes
Eli Lilly has become one of the market's most closely watched pharma stocks after a very large multi year run, and the question now is whether the cash it can generate in the future really lines up with the price investors are currently paying. With a Discounted Cash Flow (DCF) lens available, the focus turns to the stream of cash flows implied by that rally rather than the headlines alone. Over t
YahooTier 3 · providerotherlow materialitypositivereported fact
2026-09-3018:04 UTC
Eli Lilly Announces Detailed Results From The Phase 3 ACHIEVE-4 Trial Evaluating The Efficacy And Safety Of Foundayo; Foundayo Experienced A 16% Lower Risk Of MACE-4 And A 23% Lower Risk Of MACE-3, Meeting The Primary Objective For Non-inferiority Compared To Insulin Glargine
Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated
BenzingaTier 3 · providerfdahigh materialitynegativereported factmention in body only
2026-09-3017:34 UTC
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
YahooTier 3 · providerotherlow materialitynegativereported fact
2026-09-3015:31 UTC
Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - Slideshow
2026-09-30. The following slide deck was published by Eli Lilly and Company in conjunction with this event.
SeekingAlphaTier 3 · providerotherlow materialityunknownreported fact
2026-09-3014:59 UTC
Eli Lilly stock rises on striking 23% weight loss in drug combo trial
Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.
YahooTier 3 · providerotherlow materialitypositivereported factmention in body only
2026-09-3014:15 UTC
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist, in 367 adults with obesity or overweight and type 2 diab
YahooTier 3 · providerotherlow materialitymixedreported factmention in body only
2026-09-3012:03 UTC
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Eli Lilly and Company (NYSE: LLY) today announced that EBGLYSS (lebrikizumab-lbkz) monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in hand and foot skin clearance, itch and pain in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis (AD). In first-of-its-kind patient satisfaction dat
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-09-2922:00 UTC
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatru
YahooTier 3 · providerotherlow materialitynegativereported factmention in body only
2026-09-2911:00 UTC
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (semaglutide injection 7.2 mg) in adults with obesity. The findings come from an indirect treatment comparison of Zepbound and Wegovy HD, drawing
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-09-2910:21 UTC
LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding
Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.
YahooTier 3 · providerotherlow materialitypositivereported fact
2026-09-2907:08 UTC
What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?
Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeuti
YahooTier 3 · providercontractmedium materialitypositivecommentary
2026-09-2907:00 UTC
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings are based on an indirect treatment comparison of Foundayo 17.2 mg against oral se
YahooTier 3 · providerotherlow materialityunknownreported factmention in body only
2026-09-2220:11 UTC
ELI LILLY & Co: 4 filed
SEC EDGARTier 1 · primaryinsiderlow materialityunknownfact+3 duplicate reports
2026-09-1120:16 UTC
ELI LILLY & Co: 4 filed
SEC EDGARTier 1 · primaryinsiderlow materialityunknownfact
2026-09-0420:17 UTC
ELI LILLY & Co: 4 filed
SEC EDGARTier 1 · primaryinsiderlow materialityunknownfact+2 duplicate reports
hidden
62 provider-tagged items never name the company and are kept as context only.

canonical items of the last 10 sessions; analyst/industry/macro commentary and social sources excluded from the direction tally; gating uses tier 1-3 HIGH items within 3 (negative) / 2 (unknown direction) sessions

Catalysts and filings

Event	Date	In	Materiality	Source
Earnings	2026-10-29	18 sessions	high	finnhub · Tier 3 · provider

Options activity

AVAILABLE_DELAYED · session 2026-09-28 · selected contracts, delayed

Session volume: 798
5D baseline: 1,072
20D baseline: 829
Volume / 20D: 0.96x
Call / put volume: 534 / 264
Call / put ratio: 2.02
Top-3 contract share: 42%
Top expiration: 2026-10-16 77%

Activity trend · last 30 sessions

Session	Volume	5D	20D	/ 20D
2026-09-22	1,138	874	701	1.62x
2026-09-23	1,002	928	744	1.35x
2026-09-24	1,378	991	786	1.75x
2026-09-25	750	1,183	836	0.90x
2026-09-28	798	1,072	829	0.96x

Call vs put volume

calls 67%puts 33%

Expiration concentration

2026-10-16611 · 77%
2026-10-09187 · 23%

Contract concentration

O:LLY261016C01200000160 · 20%
O:LLY261016C01190000123 · 15%
O:LLY261016P0118000051 · 6%
O:LLY261016C0120500049 · 6%
O:LLY261009C0120000048 · 6%
remaining contracts58% outside top 3

Top contracts · session 2026-09-28

Contract	Type	Strike	Expiration	DTE	Volume	5D avg	20D avg	/ 20D	Return	Moneyness
O:LLY261016C01200000	CALL	1,200	2026-10-16	18	160	409	266	0.60x	5.5%	OTM (-1.3%)
O:LLY261016C01190000	CALL	1,190	2026-10-16	18	123	45	56	2.20x	-7.0%	ATM (-0.4%)
O:LLY261016P01180000	PUT	1,180	2026-10-16	18	51	33	58	0.88x	-9.5%	ATM (0.4%)
O:LLY261016C01205000	CALL	1,205	2026-10-16	18	49	12	insufficient history	insufficient history	-20.3%	OTM (-1.7%)
O:LLY261009C01200000	CALL	1,200	2026-10-09	11	48	56	23	2.05x	27.9%	OTM (-1.3%)
O:LLY261016P01165000	PUT	1,165	2026-10-16	18	43	insufficient history	insufficient history	insufficient history	-0.7%	OTM (1.7%)
O:LLY261016C01180000	CALL	1,180	2026-10-16	18	41	35	68	0.60x	-2.5%	ATM (0.4%)
O:LLY261016P01170000	PUT	1,170	2026-10-16	18	30	26	27	1.13x	-11.0%	OTM (1.3%)
O:LLY261009P01185000	PUT	1,185	2026-10-09	11	18	6	insufficient history	insufficient history	-5.7%	ATM (0.0%)
O:LLY261016P01160000	PUT	1,160	2026-10-16	18	16	48	49	0.33x	2.5%	OTM (2.1%)
O:LLY261009C01195000	CALL	1,195	2026-10-09	11	15	12	insufficient history	insufficient history	-4.6%	OTM (-0.9%)
O:LLY261016C01195000	CALL	1,195	2026-10-16	18	15	12	insufficient history	insufficient history	-2.2%	OTM (-0.9%)
O:LLY261016P01195000	PUT	1,195	2026-10-16	18	15	insufficient history	insufficient history	insufficient history	-12.1%	ITM (-0.9%)
O:LLY261016P01200000	PUT	1,200	2026-10-16	18	15	13	20	0.73x	-8.5%	ITM (-1.3%)
O:LLY261016P01175000	PUT	1,175	2026-10-16	18	14	12	insufficient history	insufficient history	0.1%	OTM (0.8%)

OPTIONS_SELECTION_M9_V1 selected contracts only · provider capability DELAYED · delayed · Top 15 selected contracts by session volume; 5D/20D averages use strictly prior sessions (M10), INSUFFICIENT_HISTORY is shown, never zero.

M13 observations for this session

Technical setup present (PRE_BREAKOUT_V1): FALSE
Technical and options context share a session: FALSE
Activity above its own 20-session baseline: FALSE
Activity below its own 20-session baseline: FALSE
Recent 5-session baseline above 20-session baseline: TRUE
Recent 5-session baseline below 20-session baseline: FALSE
Volume concentrated in top 3 contracts: FALSE
Volume concentrated in one expiration: TRUE
Calls carry most session volume: TRUE
Puts carry most session volume: FALSE
Call and put volume roughly balanced: FALSE
Enrichment data (snapshot/OI/IV/Greeks) available: FALSE
Enrichment data unavailable: TRUE
Real flow data unavailable: TRUE
Flow events present in replay window: NOT_EVALUABLE

Flow

Flow events—

Clusters—

Sweep candidates—

Block candidates—

Aggressor candidates—

Premium coverage—

Flow engine is ready. Trades and Quotes are not available with the current provider capabilities; this area populates automatically from the same M11 engine when real persisted facts exist. Synthetic fixture flow is never shown.

Evidence alerts

1 · ALERT_POLICY_V1

Category	Alert	Previous	Current	Sessions	Workflow	Actions
Data quality	Data freshness changed	TECHNICAL=CURRENT_SESSION; OPTIONS_ACTIVITY=STALE; FLOW=MISSING; ACTIVITY_PROVIDER=DELAYED	TECHNICAL=CURRENT_SESSION; OPTIONS_ACTIVITY=DELAYED; FLOW=MISSING; ACTIVITY_PROVIDER=DELAYED	2026-10-01 → 2026-10-02	New

Decision trace

PRE_BREAKOUT_SWING_V1_1 · generated 2026-10-04 18:05 UTC · strategy 073b221a9cd0…

setup_eligibleFAILNO_SETUP: failed distance_to_resistance, intermediate_trend, relative_strength_20, rsi_bandfailed_conditions=distance_to_resistance, intermediate_trend, relative_strength_20, rsi_band
finalPASSAVOID

Actions are generated from the configured trading strategy and current available market/intelligence data. They are not guarantees of future performance.